P-glycoprotein: A clue to vitamin K antagonist stabilization

Pharmacogenomics

Volumn 16, Issue 2, 2015, Pages 129-136

  Gschwind, Liliane ^a,b   Rollason, Victoria ^a   Boehlen, Françoise ^a   Rebsamen, Michela ^a   Combescure, Christophe ^a   Matthey, Alain ^a   Bonnabry, Pascal ^a,b   Dayer, Pierre ^a   Desmeules, Jules Alexandre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ABCB1; acenocoumarol; drug transporter; gene polymorphism; P glycoprotein; pharmacogenetics; vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; MULTIDRUG RESISTANCE PROTEIN; ABCB1 PROTEIN, HUMAN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ABCB1 GENE; ADULT; ANTICOAGULATION; ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG STABILITY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACENOCOUMAROL; ANTICOAGULANTS; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84921683426     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.164     Document Type: Article

References (35)

1. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e152S-e184S (2012).
2. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet. 44(12), 1227-1246 (2005).
3. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metabol. Dispos. 28(11), 1284-1290 (2000).
4. Penning-Van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemost. 86(2), 569-574 (2001).
5. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am. Fam. Physician 59(3), 635-646 (1999).
6. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet. 47(9), 565-594 (2008).
7. Gong IY, Tirona RG, Schwarz UI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118 (11), 3163-3171 (2011).
8. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013).
9. Cadamuro J, Dieplinger B, Felder T et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur. J. Clin. Pharmacol. 66(3), 253-260 (2010).
10. Schalekamp T, Brasse BP, Roijers JF et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80(1), 13-22 (2006).
11. Tassies D, Freire C, Pijoan J et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms infuence dose requirements and stability of anticoagulation. Haematologica 87(11), 1185-1191 (2002).
12. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1(1), 59-64 (2001).
13. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol. (201), 261-283 (2011).
14. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 44(2), 152-167 (2010).
15. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004).
16. Sussman NL, Waltershield M, Bulter T, Cali JJ, Riss T, Kelly JH. The predictive nature of high-throughput toxicity screening using a human hepatocyte cell line. Cell Notes (3), (2002).
17. Wadelius M, Sorlin K, Wallerman O et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4(1), 40-48 (2004).
18. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J. Clin. Pharm. Ther. 32(6), 641-649 (2007).
19. Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
20. Gschwind L, Rollason V, Daali Y, Bonnabry P, Dayer P, Desmeules JA. Role of P-glycoprotein in the uptake/effux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin. Pharmacol. Toxicol. 113(4), 259-265 (2013).
21. Tables of substrates, inhibitors and inducers of CYP450 and P-gp. www.pharmacoclin.ch/-library/pdf/cytp450pgp.pdf
22. Ansermot N, Rebsamen M, Chabert J et al. Infuence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metabol. Lett. 2(2), 76-82 (2008).
23. Schalekamp T, Van Geest-Daalderop JH, De Vries-Goldschmeding H, Conemans J, Bernsen Mj M, De Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin. Pharmacol. Ther. 75(5), 394-402 (2004).
24. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
25. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003).
26. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
27. De Oliveira Almeida VC, De Souza Ferreira AC, Ribeiro DD, Gomes Borges KB, Salles Moura Fernandes AP, Brunialti Godard AL. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J. Thromb. Haemost. 9(10), 2120-2122 (2011).
28. Kim Y, Smith A, Wu AH. C3435T polymorphism of MDR1 gene with warfarin resistance. Clin. Chim. Acta 425, 34-36 (2013).
29. Bonhomme-Faivre L, Devocelle A, Saliba F et al. MDR-1 C3435T polymorphism infuences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 78(1), 21-25 (2004).
30. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
31. Gerloff T, Schaefer M, Johne A et al. MDR1 genotypes do not infuence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 54(6), 610-616 (2002).
32. Von Ahsen N, Oellerich M, Schutz E. Limitations of genotyping based on amplicon melting temperature. Clin. Chem. 47(7), 1331-1332 (2001).
33. Reboul E, Borel P. Proteins involved in uptake, intracellular transport and basolateral secretion of fat-soluble vitamins and carotenoids by mammalian enterocytes. Prog. Lipid Res. 50(4), 388-402 (2011).
34. Foucaud-Vignault M, Soayfane Z, Menez C et al. P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice. PLoS ONE 6(9), e23614 (2011).
35. Ichihara S, Yamada Y, Kato K et al. Association of a polymorphism of ABCB1 with obesity in Japanese individuals. Genomics 91(6), 512-516 (2008).